United States Health

Summit Therapeutics (NASDAQ:SMMT) completed a $2 billion strategic equity investment from AstraZeneca (NASDAQ:AZN) to advance its clinical oncology pipeline.

Vaxcyte (NASDAQ:PCVX) reported that VAX-31 met all prespecified primary endpoints in its OPUS-1 Phase 3 trial.

Alvotech (NASDAQ:ALVO) received U.S. FDA approval to manufacture SIMLANDI drug substance in a second production suite at its Reykjavik facility.

Novartis (NYSE:NVS) signed a licensing and option agreement with privately held Abogen Biosciences worth up to about $7.8 billion for ABO2203 and other potential RNA-based programs.

Surrozen (NASDAQ:SRZN) received U.S. FDA clearance of its investigational new drug application for SZN-8141, enabling clinical development for diabetic macular edema.

Teva (NYSE:TEVA) announced new efficacy and safety analyses of ecopipam, its investigational treatment for pediatric patients with Tourette syndrome.

Integra LifeSciences (NASDAQ:IART) lowered its full-year 2026 revenue guidance to between $1.634 billion and $1.654 billion following a severe flood at its Cincinnati production facility.

Johnson & Johnson (NYSE:JNJ) announced Phase 3 clinical results showing sustained skin clearance with ICOTYDE for plaque psoriasis.

Moderna (NASDAQ:MRNA) shares climbed 2.2% to $193.01 premarket after Nasdaq said the vaccine maker will replace Warner Bros. Discovery (NASDAQ:WBD) in the Nasdaq-100 Index on October 9.

CareTrust REIT (NYSE:CTRE) agreed to acquire 45 U.K. care homes from LNT for about £1.1 billion, including 24 properties acquired for approximately £576 million in the first closing.

Cullinan Therapeutics (NASDAQ:CGEM) initiated an FDA New Drug Application for first-line zipalertinib plus chemotherapy after REZILIENT3 showed a 6.0-month median progression-free survival improvement.

Ultragenyx (NASDAQ:RARE) announced that the European Medicines Agency validated its marketing authorisation application for investigational gene therapy rebisufligene etisparvovec to treat Sanfilippo syndrome Type A.